Activity Overview
This educational activity is designed to provide expert perspectives on data presented in early 2026 regarding the use of newer anti-VEGF agents to treat neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema related to retinal vein occlusion (RVO). As part of a panel discussion, 2 expert faculty share their insights on the relevance of these findings to patient management decisions.
Target Audience
This educational activity is directed toward retina specialists, comprehensive ophthalmologists, and optometrists involved in the management of patients with neovascular retinal diseases.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Summarize key 2026 conference updates that impact management of neovascular retinal disease.
- Apply evidence to select therapy and dosing strategies for nAMD based on presentation and treatment goals.
- Apply evidence to optimize management strategies for DME.
- Evaluate evidence for interval extension in RVO using emerging data.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here